Breast cancer drug

May 2005
CMAJ: Canadian Medical Association Journal;5/24/2005, Vol. 172 Issue 11, p1432
Academic Journal
Focuses on a new treatment option for Canadian women to reduce the threat of breast cancer beyond the 5 years of tamoxifen therapy. Basis of the approval given by Health Canada for letrozole for the treatment of hormone receptor-positive early breast cancer.


Related Articles

  • Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. Julie Falardeau; John Samples; John Vetto // Breast Cancer Research & Treatment;Dec2007, Vol. 106 Issue 2, p161 

    Abstract Introduction  The main purpose of this study was to determine whether the optic cups of tamoxifen users and anastrozole users differ in size, with the cups of the tamoxifen users being smaller. Methods  Optic nerve head (ONH) topography was measured...

  • Tamoxifen: prevention is better than cure.  // PharmaWatch: Cancer;May 2003, Vol. 2 Issue 5, p21 

    Reports on the benefits of tamoxifen to women in the U.S. Growth in the market of the preventive drug; Use of the drug to prevent breast cancer; Approval of the drug as a chemopreventive agent in women.

  • Beyond Tamoxifen – Extending Endocrine Treatment for Early-Stage Breast Cancer. Burstein, Harold J. // New England Journal of Medicine;11/6/2003, Vol. 349 Issue 19, p1857 

    The author comments on a study which investigated whether extended adjuvant therapy with letrozole after 5 years of tamoxifen therapy confers a clinical advantage in breast cancer patients. Despite the fact that the switch to letrozole reduced the risk of tumor recurrence by half, the author...

  • Study Shows New Breast Cancer Drug Letrozole Shrinks Tumors More Effectively Than Tamoxifen.  // Ascribe Newswire: Medicine;12/10/2001, p18 

    A new cancer drug called letrozole (trade name Femara) worked better at shrinking breast cancer tumors than did the front-line breast cancer drug tamoxifen among a group of postmenopausal women with estrogen-positive tumors, according to a study coordinated by a Duke University Medical Center...

  • CANCER CARE: IS LESS MORE? Song, Sora // Time International (South Pacific Edition);9/13/2004, Issue 36, p67 

    The article presents information on a study that shows that breast cancer grows slowly in older women. In the study, the research was conducted on the breast-cancer survivors whose small tumors had been treated with lumpectomy and tamoxifen. In about 8% of women aged more than 50 years, cancer...

  • Tamoxifen for women at high risk of breast cancer. Nazarali, Safia A.; Narod, Steven A. // Breast Cancer: Targets & Therapy;2014, Vol. 6, p29 

    Tamoxifen has been used as a treatment for women who have been diagnosed with breast cancer for roughly four decades and has been approved as chemoprevention for over ten years. Although tamoxifen has been proven to be beneficial in preventing breast cancer in high-risk women, its use has not...

  • Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. Bertelsen, Lisbeth; Bernstein, Leslie; Olsen, Jørgen H.; Meilemkjær, Lene; Haile, Robert W.; Lynch, Charles F.; Malone, Kathleen E.; Anton-Culver, Hoda; Christensen, Jane; Langholz, Bryan; Thomas, Duncan C.; Begg, Colin B.; Capanu, Marinela; Ejlertsen, Bent; Stovall, Marilyn; Boice Jr., John D.; Shore, Roy E. // JNCI: Journal of the National Cancer Institute;1/2/2008, Vol. 100 Issue 1, p32 

    Background: Results from randomized trials indicate that treatment with tamoxifen or chemotherapy for primary breast cancer reduces the risk for contralateral breast cancer. However, less is known about how long the risk is reduced and the impact of factors such as age and menopausal status....

  • CITATIONS AND CLINICIANS' NOTES: TREATMENT -- ADJUVANT THERAPY.  // Current Medical Literature: Breast Cancer;2005, Vol. 17 Issue 1, p24 

    Provides information on several studies on adjuvant treatment for breast cancer. "Benefit and Projected Cost-Effectiveness of Anastrozole Versus Tamoxifen as Initial Adjuvant Therapy for Patients With Early-Stage Estrogen Receptor-Positive Breast Cancer," by B. E. Hillner; "Results of the ATAC...

  • Breast cancer: Tamoxifen benefits node-positive elders after mastectomy.  // Geriatrics;Aug1991, Vol. 46 Issue 8, p17 

    This article presents a study, conducted by Frank Cummings and colleagues, who analyzed findings in 168 older women with node-positive breast cancer who were treated for 2 years following mastectomy with either tamoxifen, 20 mg/d, or placebo. Of 102 deaths in this series, 61% were due to breast...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics